Peptide Graded

Semax

Does Semax work?

Partly: several Russian studies of up to 187 patients, none properly blinded.

BSome human evidenceNot approvedas of 2026-10-29

Five Russian clinical studies cover stroke (30 patients versus 80 controls in 1997; 110 patients in 2018), chronic cerebrovascular insufficiency (187 patients), optic nerve disease and a 24-person imaging study in healthy volunteers. Several had control groups but none describes randomization and blinding in the way a modern trial would, and none has been replicated outside Russia. Controlled human studies exist, so B, but at the weak end. 36781011

The 1997 stroke study treated 30 patients in the acute phase of hemispheric ischemic stroke. They got semax on top of standard care. Researchers compared them with 80 patients of similar severity on standard care alone. Recovery was faster in the semax group, especially of motor function. EEG and evoked potential measures improved. The 2018 study followed 110 patients in early or late rehabilitation after stroke, with and without semax. Semax raised blood BDNF. It was linked to faster gains on the Barthel index of daily functioning. Neither study describes randomization or blinding. 611

A 2005 study of 187 patients with chronic cerebrovascular insufficiency reported improvement with semax. The disease stabilized. There were fewer strokes and transient ischemic attacks. Side effects were few. A 2000 eye study added nasal semax to standard therapy for optic nerve disease. It reported better visual acuity, visual fields and nerve conduction than in the control group. 78

Evidence checklist

  • Randomised controlled trial Controlled but not clearly randomized
  • Human study over 100 people 187 patients in the largest study
  • More than one research group Studies from Russian groups
  • Clinical outcomes, not surrogate markers Stroke recovery and Barthel index
  • Human safety data beyond case reports FDA staff found data insufficient

Read the full Semax page

More on Semax

Citations

  1. Neuropeptides 2020: review of semax pharmacology and clinical studies doi.org
  2. STAT, July 2026: FDA peptide compounding panel outcomes statnews.com
  3. Drug Test Anal 2019: analytical and pharmacological review of semax and selank doi.org
  4. Cell Mol Neurobiol 2009: semax and BDNF and NGF expression in rat hippocampus doi.org
  5. FDA: Pharmacy Compounding Advisory Committee materials on semax, 2026 fda.gov
  6. Zh Nevrol Psikhiatr 2018: semax and rehabilitation timing after ischemic stroke pubmed.ncbi.nlm.nih.gov
  7. Zh Nevrol Psikhiatr 2005: semax in chronic cerebrovascular insufficiency pubmed.ncbi.nlm.nih.gov
  8. Vestn Oftalmol 2000: semax in optic nerve disease pubmed.ncbi.nlm.nih.gov
  9. Neurochem Res 2005: semax effects on serotonin and dopamine in rat striatum doi.org
  10. Lebedeva 2018, Bull Exp Biol Med: effects of semax on the default mode network pubmed.ncbi.nlm.nih.gov
  11. Gusev 1997, Zh Nevrol Psikhiatr: semax in acute hemispheric ischemic stroke pubmed.ncbi.nlm.nih.gov
  12. FDA: interim 503A bulk drug substances category list fda.gov
  13. Healio, July 2026: FDA committee recommends looser restrictions for several peptides healio.com
  14. HHS 2026: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with appendices A and B hhs.gov
  15. Federal Register 2026: notice of availability of the HHS peptide enforcement discretion policy, document 2026-22192, docket HHS-OASH-2026-0496 federalregister.gov
  16. Associated Press via CNN, 28 October 2026: FDA scientists opposed the move to ease peptide access edition.cnn.com

Reference information only, not medical advice. Drawn from the Semax article, fact-checked against the cited sources. No dosing anywhere on this site.